GPE vs Desmopressin

Head-to-head comparison of GPE (Glycyl-L-prolyl-L-glutamic acid) and Desmopressin (1-Deamino-8-D-arginine vasopressin) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyGPEDesmopressin
CategoryCognitive EnhancementCognitive Enhancement
Full NameGlycyl-L-prolyl-L-glutamic acid1-Deamino-8-D-arginine vasopressin
Molecular Weight301.30 Da1069.22 Da
Half-Lifeminutes1.5-3 hours
Amino Acids39
Typical Dose0.1-10 mg/kg preclinical10-40 mcg intranasal
RouteIntranasal/IntracerebroventricularIntranasal/Oral
Purity≥98%≥98%
Studies Count2535
Research StatusPre-clinicalClinical

GPE Benefits

  • memory consolidation
  • neuroprotection
  • synaptic plasticity
  • learning support

Desmopressin Benefits

  • memory consolidation
  • reduced pressor burden
  • recall support
  • short-term learning

GPE Dosing

intranasal or ICV research doses|0.1-10 mg/kg preclinical range|repeat daily or intermittent protocols

Desmopressin Dosing

intranasal research dosing|10-40 mcg or IU-equivalent studies|single-dose protocols

GPE Side Effects

  • limited human safety data
  • short half-life
  • local irritation with nasal delivery

Desmopressin Side Effects

  • hyponatremia
  • headache
  • nasal irritation

Research Overview

GPE

Preclinical studies suggest GPE can reduce neuronal damage and support plasticity-related pathways in the brain. Research interest centers on hippocampal function, which links it to learning and memory paradigms.

Desmopressin

The literature is mixed, but desmopressin has shown memory-related effects in selected populations and experimental paradigms. Its cognitive effects are usually discussed as a vasopressin-pathway probe rather than a primary nootropic.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

GPE stacks with:

davunetidenoopeptarginine-vasopressin

Desmopressin stacks with:

arginine-vasopressinnoopeptgpe
tripeptideneuroprotectionmemoryvasopressin-analogpeptide